COMMUTING TIME AND HOUSEHOLD RESPONSIBILITIES: EVIDENCE USING PROPENSITY SCORE MATCHING

The growth in women's participation in the labor force has attracted attention to the gender differences in commuting behavior, and to their implications. This study analyses the relationship between individual commuting behavior and household responsibilities, with a focus on gender differences in that relationship. Using the Dutch Time Use Surveys for the years 2000 and 2005, we analyze the relationship between commuting time, and the time devoted to home production and childcare. To deal with reverse causality, we use Propenstity Score Matching techniques to obtain imputed data for individuals. After reverse causality is taken into account, we find that the effect of home production on commuting time for women is more than double the effect for men, while childcare time has an effect on women's commuting time behavior only. Our results explain why prior studies have found that women have shorter commutes than men, shedding light on the Household Responsibility Hypothesis (HRH)

An integrated modelling methodology for estimating the prevalence of centronuclear myopathy

Centronuclear myopathies (CNM) are a group of rare inherited muscular disorders leading to a significantly reduced quality of life and lifespan. To date, CNM epidemiologic reports provide limited incidence and prevalence data. Here, an integrated model utilizing available literature is proposed to obtain a better estimate of overall CNM patient numbers by age, causative gene, severity and geographic region. This model combines published epidemiology data and extrapolates limited data over CNM subtypes, resulting in patient numbers related to age and disease subtype. Further, the model calculates a CNM incidence twofold the current estimates. The estimated incidence of 17 per million births for severe X-linked myotubular myopathy (XLMTM), the main subtype of CNM, corresponds to an estimated prevalence of 2715 in the US, 1204 in the EU, 688 in Japan and 72 in Australia. In conclusion, the model provides an estimate of the CNM incidence, prevalence and survival, and indicates that the current estimates do not fully capture the true incidence and prevalence. With rapid advances in genetic therapies, robust epidemiologic data are needed to further quantify the reliability of incidence, prevalence and survival rates for the different CNM subtypes

An integrated modelling methodology for estimating the prevalence of centronuclear myopathy.

Centronuclear myopathies (CNM) are a group of rare inherited muscular disorders leading to a significantly reduced quality of life and lifespan. To date, CNM epidemiologic reports provide limited incidence and prevalence data. Here, an integrated model utilizing available literature is proposed to obtain a better estimate of overall CNM patient numbers by age, causative gene, severity and geographic region. This model combines published epidemiology data and extrapolates limited data over CNM subtypes, resulting in patient numbers related to age and disease subtype. Further, the model calculates a CNM incidence twofold the current estimates. The estimated incidence of 17 per million births for severe X-linked myotubular myopathy (XLMTM), the main subtype of CNM, corresponds to an estimated prevalence of 2715 in the US, 1204 in the EU, 688 in Japan and 72 in Australia. In conclusion, the model provides an estimate of the CNM incidence, prevalence and survival, and indicates that the current estimates do not fully capture the true incidence and prevalence. With rapid advances in genetic therapies, robust epidemiologic data are needed to further quantify the reliability of incidence, prevalence and survival rates for the different CNM subtypes

A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women

Background: Although the male condom provides a reliable means of preventing HIV transmission, a broader choice of methods is required particularly in circumstances where the negotiation of condom use is difficult. Development of new products that may be effective as topical vaginal microbicides is the focus of a great deal of research activity currently. The novel agent PRO 2000, a naphthalene sulphonate derivative with in vitro activity against HIV and other sexually transmissible pathogens, is one such compound. We have studied the local and systemic safety and tolerance of a vaginal gel formulation of this agent at two concentrations (0.5% and 4%) over a 2 week period of daily exposure in two cohorts of healthy sexually abstinent women (one in London, UK, and the other in Antwerp, Belgium). Methods: This was a randomised, placebo controlled, double blind, three arm clinical trial conducted on two sites. Macroscopic evidence of genital epithelial changes was sought using colposcopy and evidence of microscopic inflammation was acquired using high vaginal biopsy from predetermined sites (UK cohort only). Blood levels of PRO 2000 were measured and laboratory safety tests, including coagulation screens, were performed. The impact on vaginal ecology was also assessed. Results: 73 women were enrolled across both sites (36 UK, 37 Belgium); 24, 24, 25 in the 4%, 0.5%, and placebo groups respectively. Of these, 70 completed 2 weeks' exposure to the study gel. Three (all in the 4% group) withdrew owing to adverse events which were possibly or probably gel related. Cervicovaginal abrasion was seen colposcopically in three subjects after 14 days of gel use (two in the 4% group and one in the placebo group). Genital ulceration was not seen during gel use in any of the subjects who completed the study. Histological evaluation of vaginal biopsy samples (36 women only) showed evidence of increased inflammatory signs in one participant of the 4.0% group. One volunteer in the placebo group had moderate inflammation at screening and at follow up. Severe inflammation was not seen among any of the subjects tested. Plasma levels of PRO 2000 and laboratory safety tests showed no evidence of systemic absorption. No impact was seen on normal vaginal ecology in the UK cohort where samples were taken 12 hours after the last gel application. Conclusion: In this phase I study PRO 2000 gel was found to be generally well tolerated with promising local and systemic safety profiles. The 0.5% gel was better tolerated than the 4% gel as fewer genital epithelial adverse events were seen in the former. Phase II studies are about to begin in sexually active women. Key Words: microbicide; PRO 2000; women; toxicit

BRAVER challenges students in radiation protection training in an international training

[EN] The nuclear industry is currently facing a significant demand for well-trained personnel. Due to the high market demand, it is essential to raise awareness among new target groups, including high school pupils and (pre-service) STEM teachers, about the potential and opportunities of pursuing a nuclear career. With this in mind, a new strategic partnership has been established under the Erasmus+ project 'BRAVER' (Blended and Remote teaching Activities supported by Virtual rEality for Radiation sciences). Within this 2-year project, international staff, and students from 7 partners of the CHERNE (Cooperation of Higher Education on Radiological and Nuclear Engineering) network collaborate with industry, regulatory and research institutes in developing educational virtual tools (VR and virtual online escape rooms) for nuclear sciences and engineering. The project aims to develop blended international training programs that incorporate technical, generic, and networking skills for both students and professors. This initiative can serve as a model for other scientific fields, extending its benefits to students and educators across different disciplines.This work was supported by Erasmus+: [Grant Number 21PCS0004].Vandersmissen, E.; Eerdekens, W.; Lopes, L.; Novotny, P.; Koristka, O.; Klink, M.; Laurita, R.... (2024). BRAVER challenges students in radiation protection training in an international training. Radiation Effects and Defects in Solids. https://doi.org/10.1080/10420150.2024.236418